Recipharm Advanced Bio has closed its Boxborough facility and cut about 40% of its local workforce over the past year, consolidating operations in Watertown.
Recipharm Advanced Bio has closed its Boxborough facility and cut about 40% of its local workforce over the past year, consolidating operations in Watertown.
The Sweden-based contract development and manufacturing organization shuttered its Boxborough site at 1414 Massachusetts Ave., as the manufacturer moved all its operations to its U.S. headquarters in Watertown, said Fiona Whyatt, a representative for Recipharm, in an email to WBJ.
Whyatt did not confirm when the company closed its Boxborough site. Recipharm included the site in its 2024 sustainability report, the most recent available. Recipharm last included its Boxborough location for the annual survey with WBJ’s Research Department in 2023.
Recipharm reduced its workforce from 200 local employees in 2025 to 120 in 2026. All 120 local employees are currently located in Watertown, said Whyatt.
The reduction comes four years after Recipharm completed its 2022 acquisitions of fellow Watertown-based contract development and manufacturing organization Arranta Bio and Boxborough-based virotherapy CDMO Vibalogics, according to press releases.
In January 2025, Recipharm received a three-year grant for an undisclosed sum from the Bill & Melinda Gates Foundation. The grant supported the expansion of Recipharm’s xRNA continuous manufacturing technologies into low- and middle-income countries, according to a Jan. 13, 2025 press release.
Since 2014, Recipharm has raised $241.7 million through three funding rounds, including the Gates grant, according to company financial tracker Crunchbase.
Founded in 2002, Recipharm provides drug development and manufacturing services, including formulation, production of clinical trial materials, and medical device manufacturing.
In 2024, Recipharm generated $960.44 million in revenue, according to a March 2025 press release.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare, manufacturing, and higher education industries.
